TABLE 2.
Effect of use (finger) versus nonuse (arm) sites and concentration of acid on antirhinoviral activity of salicylic and pyroglutamic acidc
| Site and treatment | Virus titers at time interval (h) after treatmenta:
|
||
|---|---|---|---|
| 0.2 | 1.0 | 3.0 | |
| Finger site | |||
| 2% iodine | >2.7 | >1.7 | 0.9b |
| 2% salicylic acid | >1.4 | >1.2 | 1.2 |
| 3.5% salicylic acid | >1.8 | >1.5 | 1.3 |
| 4.0% pyroglutamic acid | >2.0 | 1.2 | 0.5b |
| 4.68% pyroglutamic acid | >2.2 | 1.1 | 0.7 |
| 1% salicylic + 3.5% pyroglutamic acid | >2.5 | >2.0 | 1.2 |
| Arm site | |||
| 2% iodine | >2.5 | 2.1 | 1.7 |
| 2% salicylic acid | >2.1 | >1.9 | 1.4 |
a
Log reduction versus no treatment control.
b
P > 0.05 compared to control by Fisher's least significant difference two-tailed test; all other titers were significantly reduced compared to the control.
c
Assessed by reduction in rhinovirus titer compared to control treatment. Each value represents the mean of data from five individuals. The average variance of the log reduction values was 0.34 log.